EU/3/18/2125:

Benserazide hydrochloride

Overview

On 11 January 2019, orphan designation (EU/3/18/2125) was granted by the European Commission to Isabelle Ramirez, Germany, for benserazide hydrochloride for treatment of sickle cell disease.

Key facts

Active substance
Benserazide hydrochloride
Intented use
The treatment of sickle cell disease
Date of designation
11/01/2019
Orphan designation status
Positive
EU designation number
EU/3/18/2125

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Isabelle Ramirez
Steinstrasse 54
D-81667 Munich
Germany
Tel. + 49 89 67973000
Fax + 49 89 67973272
E-mail: info@zerimar.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating
Average
1 rating